CompaniesArgos Therapeutics

Argos Therapeutics

defunct

About

Defunct Company

Areas of Focus

Categories

BankruptBankrupt, Merged, Sold, Renamed or Otherwise Defunct

Clinical Trials (13)

Total Trials

13

As Lead Sponsor

10

As Collaborator

3

Total Enrollment

704

By Phase

NA: 2PHASE1: 2PHASE3: 1PHASE2: 4PHASE1/PHASE2: 3

By Status

COMPLETED: 10TERMINATED: 3

Clinical Trials Pipeline13 trials

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Phase 1/2

Phase 2/3

N/A

Phase

Status

Role

Condition

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

Today

Hover over trial bars to see details

Recent Trials

NCT02026960Collaborator

RNA Extraction and Amplification From Biopsy Specimens in Subjects With Metastatic Renal Cell Carcinoma (AGS-NTS-017)

14 participants

Started: Mar 31, 2014 · Completed: Sep 7, 2017

NCT02042248Collaborator

A Phase I Study to Evaluate the Immunologic Response and Virologic Impact of AGS-004

PHASE1Completed

Started: Mar 31, 2014 · Completed: May 31, 2016

NCT02143492Lead Sponsor

Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC

11 participants

Started: Aug 31, 2013 · Completed: Jul 31, 2015

NCT01582672Lead Sponsor

Phase 3 Trial of Autologous Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma

PHASE3Terminated

462 participants

Started: Nov 30, 2012 · Completed: Apr 30, 2018

NCT01482949Lead Sponsor

A Rollover Protocol for Subjects Previously Treated With AGS-003

PHASE2Terminated

Started: Sep 30, 2011 · Completed: May 31, 2018

View all 13 trials →

Funding History (20)

8-K

May 3, 2019

8-K

Dec 3, 2018

8-K

Jul 20, 2018

8-K

Apr 24, 2018

8-K

Apr 19, 2018

8-K

Apr 2, 2018

8-K

Mar 7, 2018

8-K

Feb 16, 2018

8-K

Feb 5, 2018

8-K/A

Jan 30, 2018